Expanding Global Capabilities Sirio Pharma's strategic acquisition of Best Formulations in 2023 has significantly increased its manufacturing capacity and technological capabilities, especially in North America, offering growth opportunities for partners seeking reliable contract manufacturing in key markets.

Diverse Product Portfolio With extensive expertise across various delivery formats such as gummies, softgels, capsules, powders, and functional beverages, Sirio can cater to a wide range of nutraceutical product needs, making it an ideal partner for brands looking to expand or diversify their product lines.

Established Industry Presence Founded in 1993 and operating multiple state-of-the-art manufacturing facilities across the US, Germany, and China, Sirio demonstrates a strong manufacturing foundation and proven track record, which assures quality and reliability for potential clients.

Financial Stability Generating revenues between 100 million and 250 million dollars, Sirio exhibits solid financial performance that supports capacity expansion and ongoing innovation, reducing risk for clients considering long-term manufacturing partnerships.

Market Positioning As a leading global nutraceutical CDMO with recent strategic acquisitions and a broad product development focus, Sirio is well-positioned to meet growing demand in the health and wellness market, presenting opportunities for collaboration with emerging and established brands seeking scalable manufacturing solutions.